tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Fumiyoshi Sakai

Fumiyoshi Sakai

Credit Suisse
Wall Street Analyst
Ranked #3,934 out of 8,045 Analysts on TipRanks (#8,611 out of 21,519 overall experts)

Success Rate

67%
4 out of 6 Profitable Transactions

Average Return

10.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Fumiyoshi Sakai's ratings since 2014 and opened each position for the duration of 1 Year:
66.67% of your transactions would have been profitable with an average return of 10.3%

Stock Rating Distribution

12Ratings
50.00% Hold
25.00% Buy
25.00% Sell
Distribution of Fumiyoshi Sakai's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Taisho Pharmaceutical Holdings Co
(TAISF)
Rating Type:Sell
Dates:Jun 25, 2021 - Jun 25, 2022
Gain:44.50%
The most profitable rating made by Fumiyoshi Sakai

Fumiyoshi Sakai's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Terumo
Aug 19, 2014
Buy
Upgraded
100%
+12.20%
1
Otsuka Holdings Co
Jun 18, 2019
Hold
Downgraded
0.00%
1
Santen Pharmaceutical Co
Jun 29, 2020
Hold
Downgraded
0.00%
1
Nov 18, 2020
Buy
Upgraded
0%
-29.30%
1
Sumitomo Dainippon Pharma Co
Mar 22, 2021
Sell
Reiterated
100%
+29.15%
3
Taisho Pharmaceutical Holdings Co
Jun 25, 2021
Sell
Downgraded
$41.26
(4.60% Upside)
100%
+44.50%
1
ONO Pharmaceutical Co
Sep 08, 2021
Hold
Reiterated
$21.01
(-15.63% Downside)
0.00%
1
TWAPF
Towa Pharmaceutical Co
Nov 15, 2021
Hold
Reiterated
0.00%
2
Shionogi & Co
Dec 13, 2021
Buy
Reiterated
$67.52
(28.01% Upside)
0%
-23.50%
1
List of latest recommendations made by Fumiyoshi Sakai. Click to expand and see Fumiyoshi Sakai's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More